Scientists from the Higher Council for Scientific Research (CSIC) have participated in the development, tuning and validation of a new test to detect antibodies to the SARS-Cov2 virus, which is the cause of the current pandemic. The project, called SCOVAM (for SARS COV -2 Antigen Microarray ), is based on the use of biochips or microarrays initially designed to track life on other planets and uses several of the SARS-Cov2 virus proteins, which improves reliability and the ability to detect antibodies against other methods. Researchers at the Center for Astrobiology (CAB, CSIC-INTA) have been developing fluorescent immunoassays and instrumentation for almost two decades to detect molecular traces of life in extreme environments for

planetary exploration, specifically, on Buy Email Database & Build Email List Quickly Mars. The same technology, also used to search for life in the deep ocean, has now been used to simultaneously detect IgM and IgG antibodies in blood serum. The fluorescence detection method is slower (about three hours, approximately) than the rapid test (or lateral flow) but, on the other hand, it is much more sensitive (it is capable of detecting a smaller amount of antibodies), it is semi-quantitative, scalable and automatable, since it can be operated in multiple formats (up to 96 samples simultaneously) and the data is stored in digital format. “An advantage of SCOVAM is that it uses several of the virus proteins to capture antibodies present in the blood serum that are capable of specifically binding to SARS-

Buy Email Database & Build Email List Quickly
CoV2. Having several viral proteins as a hook allows the identification of antigenic patterns of the virus, since each person can develop a different antibody response to the different proteins. On the other hand, in the event that future research identifies predictive markers of the evolution of the disease, SCOVAM could be adapted and updated for the simultaneous detection of antibodies and inflammation markers, for example ”, explains researcher Víctor Parro , who works in the CAB (CSIC-INTA). The method developed at the CAB shows a match greater than 91% with the commercial tests and, in several cases, corrects the false negative results of the PCR (Polymerase Chain Reaction). “It should be noted that 9% of discrepancies can be attributed

Leave a Reply

Your email address will not be published. Required fields are marked *